AM Sciences Inc. has reported compounds acting as lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists described as potentially useful for the treatment of fibrosis.

After hours: December 30 at 4:00:09 PM EST Loading Chart for CTNM ...

which has lead candidate BMS-986020 – a lysophosphatidic acid (LPA1) receptor antagonist – in phase II testing for IPF. In November 2014, BMS reached an agreement to acquire Galecto Biotech in ...

Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive ...

into a signalling molecule known as lysophosphatidic acid (LPA). These signals can induce various responses along multiple cellular signalling pathways that lead to a build up of fibroblasts.

1 First Teaching Hospital of Tianjin University of Traditional Chinese Medicine/National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China 2 Postgraduate School ...

School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China Diabetes is a significant global health issue, causing extensive morbidity and mortality, and ...

After hours: December 26 at 6:56:47 p.m. EST ...

Clin Lipidology. 2013;8(3):345-359.

Contineum Therapeutics is a clinical stage biopharmaceutical company that focuses on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I ...